Spots Global Cancer Trial Database for hepatocellular carcinoma recurrent
Every month we try and update this database with for hepatocellular carcinoma recurrent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | NCT02423343 | Solid Tumor Non-Small Cell ... Hepatocellular ... | Galunisertib Nivolumab | 18 Years - | Eli Lilly and Company | |
| A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene | NCT05497453 | Hepatocellular ... Solid Tumor Hepatocellular ... Hepatocellular ... Hepatocellular ... Liver Cancer Liver, Cancer o... | OTX-2002 Tyrosine kinase... Tyrosine kinase... Checkpoint Inhi... | 18 Years - | Omega Therapeutics | |
| A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | NCT05417932 | Hepatitis B Vir... Hepatocellular ... | SCG101 | 18 Years - 70 Years | SCG Cell Therapy Pte. Ltd. | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | NCT02423343 | Solid Tumor Non-Small Cell ... Hepatocellular ... | Galunisertib Nivolumab | 18 Years - | Eli Lilly and Company | |
| Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis | NCT05990959 | Hepatocellular ... Surgery | No intervention... | 20 Years - | China Medical University Hospital | |
| Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant | NCT04425226 | Liver Transplan... Hepatocellular ... | Pembrolizumab I... Lenvatinib Oral... | 18 Years - 80 Years | RenJi Hospital | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence | NCT04506398 | Hepatocellular ... Liver Transplan... | liver transplan... ctDNA whole exome seq... | 18 Years - 80 Years | RenJi Hospital | |
| QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | NCT03563170 | Hepatocellular ... Hepatocellular ... | ETBX-011 GI-4000 haNK for infusi... avelumab Capecitabine Cyclophosphamid... 5-Fluorouracil Leucovorin nab-Paclitaxel Sorafenib SBRT Aldoxorubicin h... ETBX-051 ETBX-061 GI-6207 GI-6301 Cetuximab N-803 | 18 Years - | ImmunityBio, Inc. | |
| A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection | NCT04392700 | Hepatocellular ... | Tenofovir disop... Entecavir 0.5 m... | 18 Years - 80 Years | Sun Yat-sen University | |
| Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis | NCT05990959 | Hepatocellular ... Surgery | No intervention... | 20 Years - | China Medical University Hospital | |
| Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma | NCT06254248 | Liver Transplan... Hepatocellular ... Systemic Treatm... | Systemic therap... | 18 Years - 90 Years | Assistance Publique - Hôpitaux de Paris | |
| Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant | NCT06233708 | Hepatocellular ... Hepatocellular ... | Non-Selective B... | 18 Years - | Asan Medical Center | |
| QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | NCT03563170 | Hepatocellular ... Hepatocellular ... | ETBX-011 GI-4000 haNK for infusi... avelumab Capecitabine Cyclophosphamid... 5-Fluorouracil Leucovorin nab-Paclitaxel Sorafenib SBRT Aldoxorubicin h... ETBX-051 ETBX-061 GI-6207 GI-6301 Cetuximab N-803 | 18 Years - | ImmunityBio, Inc. | |
| Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study) | NCT05277675 | Hepatocellular ... | Tislelizumab/Si... RFA | 18 Years - 75 Years | Southwest Hospital, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
